Rationale and Therapeutic Opportunities for Natriuretic Peptide System Augmentation in Heart Failure

Current Heart Failure Reports

Volumn 12, Issue 1, 2015, Pages 7-14

  McKie, Paul M ^a   Burnett, John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cyclic guanosine monophosphate (cGMP); Heart failure; Natriuretic peptide; Neprilysin; Neutral endopeptidase; Preclinical

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; MEMBRANE METALLOENDOPEPTIDASE INHIBITOR; METALLOPROTEINASE INHIBITOR; NATRIURETIC PEPTIDE TYPE C; UNCLASSIFIED DRUG; NATRIURETIC FACTOR; PROTEINASE INHIBITOR;

DRUG DELIVERY SYSTEM; DRUG TARGETING; ENZYME INHIBITION; HEART FAILURE; HUMAN; NONHUMAN; PROTEIN DEFICIENCY; REVIEW; SUPPLEMENTATION; ANTAGONISTS AND INHIBITORS; DEFICIENCY; DRUG COMBINATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG THERAPY, COMBINATION; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDES; NEPRILYSIN; PROTEASE INHIBITORS;

EID: 84936775156     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-014-0235-3     Document Type: Review

References (108)

1. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:1977–2016.
2. Yancy CW, Jessup M, Bozkurt B, et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147–239.
3. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6:606–19.
4. Go AS, Mozaffarian D, Roger VL, et al. Executive summary: heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129:399–410.
5. Dunlay SM, Shah ND, Shi Q, et al. Lifetime costs of medical care after heart failure diagnosis. Circ Cardiovasc Qual Outcome. 2011;4:68–75.
6. Braunwald E. Heart failure. JACC Heart Fail. 2013;1:1–20.
7. Kangawa K, Matsuo H. Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP). Biochem Biophys Res Commun. 1984;118:131–9.
8. Flynn TG, de Bold ML, de Bold AJ. The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem Biophys Res Commun. 1983;117:859–65.
9. Hunter I, Rehfeld JF, Goetze JP. Measurement of the total proANP product in mammals by processing independent analysis. J Immunol Methods. 2011;370:104–10.
10. Ichiki T, Huntley BK, Heublein DM, et al. Corin is present in the normal human heart, kidney, and blood, with pro-B-type natriuretic peptide processing in the circulation. Clin Chem. 2011;57:40–7.
11. Burnett Jr JC, Granger JP, Opgenorth TJ. Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol. 1984;247:F863–6.
12. LR Potter, AR Yoder, DR Flora, LK Antos, DM Dickey. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 2009:341–66. A well written overview of the natriuretic peptide system.
13. Huntley BK, Sandberg SM, Noser JA, et al. BNP-induced activation of cGMP in human cardiac fibroblasts: interactions with fibronectin and natriuretic peptide receptors. J Cell Physiol. 2006;209:943–9.
14. Lopez MJ, Wong SK, Kishimoto I, et al. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature. 1995;378:65–8.
15. Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun. 1990;168:863–70.
16. Clavell AL, Stingo AJ, Wei CM, Heublein DM, Burnett Jr JC. C-type natriuretic peptide: a selective cardiovascular peptide. Am J Physiol. 1993;264:R290–5.
17. Sangaralingham SJ, Huntley BK, Martin FL, et al. The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic Peptide. Hypertension. 2011;57:201–7.
18. Horio T, Tokudome T, Maki T, et al. Gene expression, secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts. Endocrinology. 2003;144:2279–84.
19. Soeki T, Kishimoto I, Okumura H, et al. C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J Am Coll Cardiol. 2005;45:608–16.
20. Rubattu S, Sciarretta S, Morriello A, Calvieri C, Battistoni A, Volpe M. NPR-C: a component of the natriuretic peptide family with implications in human diseases. J Mol Med (Berl). 2010;88:889–97.
21. Anand-Srivastava MB. Natriuretic peptide receptor-C signaling and regulation. Peptides. 2005;26:1044–59.
22. Charles CJ, Espiner EA, Nicholls MG, et al. Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am J Physiol. 1996;271:R373–80.
23. Ralat LA, Guo Q, Ren M, et al. Insulin-degrading enzyme modulates the natriuretic peptide-mediated signaling response. J Biol Chem. 2011;286:4670–9.
24. Potter LR. Natriuretic peptide metabolism, clearance and degradation. FEBS J. 2011;278:1808–17.
25. Graf K, Koehne P, Grafe M, Zhang M, Auch-Schwelk W, Fleck E. Regulation and differential expression of neutral endopeptidase 24.11 in human endothelial cells. Hypertension. 1995;26:230–5.
26. Kerr MA, Kenny AJ. The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. Biochem J. 1974;137:477–88.
27. Roques BP, Noble F, Dauge V, Fournie-Zaluski MC, Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev. 1993;45:87–146.
28. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J. 1993;291(Pt 1):83–8.
29. Vanneste Y, Michel A, Dimaline R, Najdovski T, Deschodt-Lanckman M. Hydrolysis of alpha-human atrial natriuretic peptide in vitro by human kidney membranes and purified endopeptidase-24.11. Evidence for a novel cleavage site. Biochem J. 1988;254:531–7.
30. Watanabe Y, Nakajima K, Shimamori Y, Fujimoto Y. Comparison of the hydrolysis of the three types of natriuretic peptides by human kidney neutral endopeptidase 24.11. Biochem Mol Med. 1997;61:47–51.
31. Dickey DM, Yoder AR, Potter LR. A familial mutation renders atrial natriuretic Peptide resistant to proteolytic degradation. J Biol Chem. 2009;284:19196–202.
32. McKie PM, Cataliotti A, Boerrigter G, et al. A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension. Hypertension. 2010;56:1152–9.
33. Burnett Jr JC, Kao PC, Hu DC, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 1986;231:1145–7.
34. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–7.
35. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet. 1994;343:440–4.
36. McKie PM, Burnett Jr JC. B-type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities. Mayo Clin Proc. 2005;80:1029–36.
37. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, von Scheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol. 2001;38:1934–41.
38. Hartmann F, Packer M, Coats AJ, et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation. 2004;110:1780–6.
39. Miller WL, Hartman KA, Burritt MF, et al. Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation. 2007;116:249–57.
40. Hawkridge AM, Heublein DM, Bergen 3rd HR, Cataliotti A, Burnett Jr JC, Muddiman DC. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A. 2005;102:17442–7.
41. Niederkofler EE, Kiernan UA, O’Rear J, et al. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail. 2008;1:258–64.
42. Waldo SW, Beede J, Isakson S, et al. Pro-B-type natriuretic peptide levels in acute decompensated heart failure. J Am Coll Cardiol. 2008;51:1874–82.
43. Macheret F, Boerrigter G, McKie P, et al. Pro-B-type natriuretic peptide(1–108) circulates in the general community: plasma determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2011;57:1386–95.
44. Lam CS, Burnett Jr JC, Costello-Boerrigter L, Rodeheffer RJ, Redfield MM. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol. 2007;49:1193–202.
45. Nishikimi T, Kuwahara K, Nakagawa Y, Kangawa K, Minamino N, Nakao K. Complexity of molecular forms of B-type natriuretic peptide in heart failure. Heart. 2013;99:677–9.
46. Miller WL, Phelps MA, Wood CM, et al. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ Heart Fail. 2011;4:355–60.
47. Liang F, O’Rear J, Schellenberger U, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol. 2007;49:1071–8.
48. Heublein DM, Huntley BK, Boerrigter G, et al. Immunoreactivity and guanosine 3′,5′-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension. 2007;49:1114–9.
49. Costello-Boerrigter LC, Boerrigter G, Redfield MM, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2006;47:345–53.
50. Tonne JM, Campbell JM, Cataliotti A, et al. Secretion of glycosylated pro-B-type natriuretic peptide from normal cardiomyocytes. Clin Chem. 2011;57:864–73.
51. Schellenberger U, O’Rear J, Guzzetta A, Jue RA, Protter AA, Pollitt NS. The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch Biochem Biophys. 2006;451:160–6.
52. Ibebuogu UN, Gladysheva IP, Houng AK, Reed GL. Decompensated heart failure is associated with reduced corin levels and decreased cleavage of pro-atrial natriuretic peptide. Circ Heart Fail. 2011;4:114–20.
53. Gomez N, Touihri K, Matheeussen V, et al. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur J Heart Fail. 2012;14:14–21.
54. Gladysheva IP, Wang D, McNamee RA, et al. Corin overexpression improves cardiac function, heart failure, and survival in mice with dilated cardiomyopathy. Hypertension. 2013;61:327–32.
55. McKie PM, Schirger JA, Costello-Boerrigter LC, et al. Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction. J Am Coll Cardiol. 2011;58:2095–103.
56. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343:246–53.
57. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531–40.
58. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487–91.
59. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900–5.
60. O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32–43.
61. Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA. 2013;310:2533–43.
62. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240–327.
63. Hata N, Seino Y, Tsutamoto T, et al. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study. Circ J. 2008;72:1787–93.
64. Morita Y, Kohsaka S, Oshima K, Yoshikawa T, Fukuda K. Use of carperitide infusion for acutely decompensated heart failure. Crit Care. 2012;16:406.
65. Chen HH, Glockner JF, Schirger JA, Cataliotti A, Redfield MM, Burnett Jr JC. Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. J Am Coll Cardiol. 2012;60:2305–12. The first study to describe the cardiorenal effects of chronic BNP administration in human heart failure.
66. PM McKie, JA Schirger, A Cataliotti et al. Asymptomatic Left Ventricular Systolic Dysfunction (Stage B Heart Failure) and Response to Chronic Protein Therapy With SQ BNP. Circulation 2013;128.
67. Ahmad T, Felker GM. Subcutaneous B-type natriuretic peptide for treatment of heart failure: a dying therapy reborn? J Am Coll Cardiol. 2012;60:2313–5.
68. Cataliotti A, Schirger JA, Martin FL, et al. Oral human brain natriuretic peptide activates cyclic guanosine 3′,5′-monophosphate and decreases mean arterial pressure. Circulation. 2005;112:836–40.
69. Martin FL, Stevens TL, Cataliotti A, et al. Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure. Kidney Int. 2005;67:1723–30.
70. Chen HH, Schirger JA, Chau WL, et al. Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure. Circulation. 1999;100:2443–8.
71. Northridge DB, Currie PF, Newby DE, et al. Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. Eur J Heart Fail. 1999;1:67–72.
72. Northridge DB, Newby DE, Rooney E, Norrie J, Dargie HJ. Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure. Am Heart J. 1999;138:1149–57.
73. Newby DE, McDonagh T, Currie PF, Northridge DB, Boon NA, Dargie HJ. Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition. Eur Heart J. 1998;19:1808–13.
74. Kentsch M, Otter W, Drummer C, Notges A, Gerzer R, Muller-Esch G. Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure. Eur J Clin Pharmacol. 1996;51:269–72.
75. McDowell G, Coutie W, Shaw C, Buchanan KD, Struthers AD, Nicholls DP. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmacol. 1997;43:329–32.
76. Cleland JG, Swedberg K. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators. Lancet. 1998;351:1657–8.
77. Ferro CJ, Spratt JC, Haynes WG, Webb DJ. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation. 1998;97:2323–30.
78. Andreatta-van Leyen S, Romero MF, Khosla MC, Douglas JG. Modulation of phospholipase A2 activity and sodium transport by angiotensin-(1–7). Kidney Int. 1993;44:932–6.
79. DelliPizzi AM, Hilchey SD, Bell-Quilley CP. Natriuretic action of angiotensin(1–7). Br J Pharmacol. 1994;111:1–3.
80. Handa RK, Ferrario CM, Strandhoy JW. Renal actions of angiotensin-(1–7): in vivo and in vitro studies. Am J Physiol. 1996;270:F141–7.
81. Sampaio WO, Nascimento AA, Santos RA. Systemic and regional hemodynamic effects of angiotensin-(1–7) in rats. Am J Physiol Heart Circ Physiol. 2003;284:H1985–94.
82. Ren Y, Garvin JL, Carretero OA. Vasodilator action of angiotensin-(1–7) on isolated rabbit afferent arterioles. Hypertension. 2002;39:799–802.
83. Maki T, Nasa Y, Tanonaka K, Takahashi M, Takeo S. Beneficial effects of sampatrilat, a novel vasopeptidase inhibitor, on cardiac remodeling and function of rats with chronic heart failure following left coronary artery ligation. J Pharmacol Exp Ther. 2003;305:97–105.
84. Allikmets K. Sampatrilat Shire. Curr Opin Investig Drugs. 2002;3:578–81.
85. Wallis EJ, Ramsay LE, Hettiarachchi J. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension. Clin Pharmacol Ther. 1998;64:439–49.
86. Trippodo NC, Robl JA, Asaad MM, Fox M, Panchal BC, Schaeffer TR. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens. 1998;11:363–72.
87. Weber MA. Vasopeptidase inhibitors. Lancet. 2001;358:1525–32.
88. Chen HH, Cataliotti A, Burnett Jr JC. Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: insights from experimental heart failure. Curr Hypertens Rep. 2001;3 Suppl 2:S15–21.
89. Troughton RW, Rademaker MT, Powell JD, et al. Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure. Hypertension. 2000;36:523–30.
90. Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 2000;356:615–20.
91. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106:920–6.
92. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103–11.
93. Fryer RM, Segreti J, Banfor PN, et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol. 2008;153:947–55.
94. Adam A, Cugno M, Molinaro G, Perez M, Lepage Y, Agostoni A. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet. 2002;359:2088–9.
95. von Lueder TG, Sangaralingham SJ, Wang BH, et al. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail. 2013;6:594–605.
96. Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50:401–14.
97. Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255–66. A large study which assesses the effects of LCZ696 in human hypertensive disease.
98. McMurray JJ, Packer M, Desai AS, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013;15:1062–73. This methods paper lays the groundwork for the upcoming PARADIGM-HF paper to be published in late 2014 or early 2015.
99. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387–95. This study assesses the effects of LCZ696 in heart failure with preserved ejection fraction and demonstrates promising results including a reduction in NT-proBNP levels.
100. Newton-Cheh C, Larson MG, Vasan RS, et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet. 2009;41:348–53.
101. Cannone V, Boerrigter G, Cataliotti A, et al. A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. J Am Coll Cardiol. 2011;58:629–36.
102. McKie PM, Cataliotti A, Huntley BK, Martin FL, Olson TM, Burnett Jr JC. A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions. J Am Coll Cardiol. 2009;54:1024–32.
103. Lisy O, Huntley BK, McCormick DJ, Kurlansky PA, Burnett Jr JC. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol. 2008;52:60–8.
104. McKie PM, Sangaralingham SJ, Burnett Jr JC. CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease. Curr Heart Fail Rep. 2010;7:93–9.
105. CY Lee, G Boerrigter, HH Chen et al. Cardiorenal and Neurohumoral Actions of a Novel Designer Natriuretic Peptide, CU-NP, In Canine Experimental Heart Failure. Circulation 2008;118:S293.
106. Pan SC, Chen HH, Dickey DM, et al. Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide. Proc Natl Acad Sci U S A. 2009;106:11282–7.
107. McKie PM, Cataliotti A, Ichiki T, Sangaralingham SJ, Chen HH, Burnett Jr JC. M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics. J Am Heart Assoc. 2014;3:e000206.
108. Cataliotti A, Chen HH, Schirger JA, et al. Chronic Actions of a Novel Oral B-Type Natriuretic Peptide Conjugate in Normal Dogs and Acute Actions in Angiotensin II-Mediated Hypertension. Circulation. 2008;118:1729–36.